BeiGene (HKSE:06160) Change In Inventory : HK$-1,291 Mil (TTM As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is BeiGene Change In Inventory?

BeiGene's change in inventory for the quarter that ended in Mar. 2024 was HK$-292 Mil. It means BeiGene's inventory increased by HK$292 Mil from Dec. 2023 to Mar. 2024 .

BeiGene's change in inventory for the fiscal year that ended in Dec. 2023 was HK$-1,101 Mil. It means BeiGene's inventory increased by HK$1,101 Mil from Dec. 2022 to Dec. 2023 .

BeiGene's Total Inventories for the quarter that ended in Mar. 2024 was HK$3,500 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. BeiGene's Days Inventory for the quarter that ended in Mar. 2024 was 315.07.

Inventory Turnover measures how fast the company turns over its inventory within a year. BeiGene's Inventory Turnover for the quarter that ended in Mar. 2024 was 0.29.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. BeiGene's Inventory-to-Revenue for the quarter that ended in Mar. 2024 was 0.57.

BeiGene Change In Inventory Historical Data

The historical data trend for BeiGene's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BeiGene Change In Inventory Chart

BeiGene Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Change In Inventory

Get a 7-Day Free Trial

-96.08

-456.63

-1,195.84

-441.35

-1,100.78

BeiGene Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Inventory	Get a 7-Day Free Trial															-102.25	-317.79	9.61	-691.77	-291.52

BeiGene Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was HK$-1,291 Mil.

BeiGene (HKSE:06160) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

BeiGene's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	3374.705	/	977.367	*	365 / 4
	=	315.07

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

BeiGene's Inventory Turnover for the quarter that ended in Mar. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	977.367	/	3374.705
	=	0.29

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

BeiGene's Inventory to Revenue for the quarter that ended in Mar. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	3374.705	/	5880.174
	=	0.57

BeiGene Change In Inventory Related Terms

Thank you for viewing the detailed overview of BeiGene's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

BeiGene (HKSE:06160) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BeiGene Ltd (HKSE:06160) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

BGNE:USA 49BA:Germany 688235:China B1GN34:Brazil

Address

c/o Mourant Governance Services (Cayman) Limited, 94 Solaris Avenue, Camana Bay, Grand Cayman, CYM, KY1-1108

Website

https://www.beigene.com

BeiGene Ltd is a commercial-stage biotechnology company. It is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. The company has developed a proprietary cancer biology platform that addresses the importance of tumor-immune system interactions and the value of primary biopsies in developing new models to support its drug discovery effort. It has developed clinical-stage drug candidates that inhibit the important oncology targets Bruton's tyrosine kinase, or BTK; RAF dimer protein complex and PARP family of proteins, and an immuno-oncology agent that inhibits the immune checkpoint protein receptor PD-1. Its geographical segments are China, the United States, and the Rest of the world.

Executives

Jpmorgan Chase & Co.	2502 Approved lending agent
Oyler John Victor	2101 Beneficial owner
The Capital Group Companies, Inc.	2201 Interest of corporation controlled by you
Baker Felix James	2201 Interest of corporation controlled by you
Baker Julian Charles	2201 Interest of corporation controlled by you
Baker Bros. Advisors (gp) Llc	2201 Interest of corporation controlled by you
Baker Brothers Life Sciences Capital, L.p.	2201 Interest of corporation controlled by you
Hhlr Advisors, Ltd.	2102 Investment manager
Hhlr Fund, L.p.	2101 Beneficial owner
Amgen Inc.	2101 Beneficial owner
Hillhouse Capital Advisors, Ltd.	2102 Investment manager
Gaoling Fund, L.p.	2101 Beneficial owner
Fidelity Management & Research Company
Fmr Co., Inc.

BeiGene (HKSE:06160) Headlines

No Headlines